Tsukuda M, Furukawa S, Sawaki S, Kubota A
Department of Otorhinolaryngology, School of Medicine, Yokohama City University, Kanagawa, Japan.
ORL J Otorhinolaryngol Relat Spec. 1994 Mar-Apr;56(2):101-4. doi: 10.1159/000276619.
Recombinant human granulocyte colony-stimulating factor (rG-CSF) was used for the amelioration of neutropenia caused by cisplatin-based chemotherapy in head and neck cancer patients. For a dose-finding study of rG-CSF, 11 patients, who had levels of absolute neutrophil counts below 500/mm3 in peripheral blood, were administered rG-CSF subcutaneously at a dose of 1 or 2 micrograms/kg for 5 days. A 'useful' rate in 1 and 2 micrograms/kg was obtained in 71.4 and 100% of patients, respectively. In 6 patients, the clinical utility of rG-CSF at a dosage of 2 micrograms/kg from the day after chemotherapy for 10 consecutive days was observed. The percentage of 'very useful' evaluations was 83.3% (5/6). No side effects or abnormal laboratory findings were observed in any patients after administration of rG-CSF.
重组人粒细胞集落刺激因子（rG-CSF）用于改善头颈部癌患者顺铂化疗引起的中性粒细胞减少。在一项rG-CSF的剂量探索研究中，11例外周血绝对中性粒细胞计数低于500/mm³的患者，以1或2微克/千克的剂量皮下注射rG-CSF，持续5天。1微克/千克和2微克/千克剂量组的“有效”率分别为71.4%和100%。观察了6例患者在化疗后次日起连续10天使用2微克/千克剂量rG-CSF的临床疗效。“非常有效”评估的比例为83.3%（5/6）。给予rG-CSF后，所有患者均未观察到副作用或实验室检查异常结果。
